 | • レポートコード：GIR-105X00154 • 出版社/出版日：GlobalInfoResearch / 2021年5月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、急性片頭痛治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。急性片頭痛治療薬の種類別市場規模（トリプタン、NSAID、その他）、用途別市場規模（ドラッグストア、病院薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・急性片頭痛治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：GSK、Teva、Pfizer、Novartis、Merck、Sun Pharma、Grunenthal、Endo Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：トリプタン、NSAID、その他 ・用途別分析2016年-2026年：ドラッグストア、病院薬局 ・急性片頭痛治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・急性片頭痛治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・急性片頭痛治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・急性片頭痛治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・急性片頭痛治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Acute Migraine Medications market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Acute Migraine Medications size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Acute Migraine Medications market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Acute Migraine Medications market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Triptans
NSAIDs
Others
Market segment by Application can be divided into
Drug Stores
Hospital Pharmacies
The key market players for global Acute Migraine Medications market are listed below:
GSK
Teva
Pfizer
Novartis
Merck
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Acute Migraine Medications product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Acute Migraine Medications, with price, sales, revenue and global market share of Acute Migraine Medications in 2018 and 2019.
Chapter 3, the Acute Migraine Medications competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Acute Migraine Medications breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Acute Migraine Medications market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Acute Migraine Medications sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Acute Migraine Medications Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Acute Migraine Medications Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Triptans
1.2.3 NSAIDs
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Acute Migraine Medications Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Drug Stores
1.3.3 Hospital Pharmacies
1.4 Global Acute Migraine Medications Market Size & Forecast
1.4.1 Global Acute Migraine Medications Sales in Value (2016-2026))
1.4.2 Global Acute Migraine Medications Sales in Volume (2016-2026)
1.4.3 Global Acute Migraine Medications Price by Type (2016-2026) & (US$/Unit)
1.5 Global Acute Migraine Medications Production Capacity Analysis
1.5.1 Global Acute Migraine Medications Total Production Capacity (2016-2026)
1.5.2 Global Acute Migraine Medications Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Acute Migraine Medications Market Drivers
1.6.2 Acute Migraine Medications Market Restraints
1.6.3 Acute Migraine Medications Trends Analysis
2 Manufacturers Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Acute Migraine Medications Product and Services
2.1.4 GSK Acute Migraine Medications Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Teva
2.2.1 Teva Details
2.2.2 Teva Major Business
2.2.3 Teva Acute Migraine Medications Product and Services
2.2.4 Teva Acute Migraine Medications Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Acute Migraine Medications Product and Services
2.3.4 Pfizer Acute Migraine Medications Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Acute Migraine Medications Product and Services
2.4.4 Novartis Acute Migraine Medications Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Merck
2.5.1 Merck Details
2.5.2 Merck Major Business
2.5.3 Merck Acute Migraine Medications Product and Services
2.5.4 Merck Acute Migraine Medications Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Sun Pharma
2.6.1 Sun Pharma Details
2.6.2 Sun Pharma Major Business
2.6.3 Sun Pharma Acute Migraine Medications Product and Services
2.6.4 Sun Pharma Acute Migraine Medications Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Grunenthal
2.7.1 Grunenthal Details
2.7.2 Grunenthal Major Business
2.7.3 Grunenthal Acute Migraine Medications Product and Services
2.7.4 Grunenthal Acute Migraine Medications Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Endo Pharmaceuticals
2.8.1 Endo Pharmaceuticals Details
2.8.2 Endo Pharmaceuticals Major Business
2.8.3 Endo Pharmaceuticals Acute Migraine Medications Product and Services
2.8.4 Endo Pharmaceuticals Acute Migraine Medications Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Acute Migraine Medications Sales by Manufacturer
3.1 Global Acute Migraine Medications Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Acute Migraine Medications Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Acute Migraine Medications
3.4 Market Concentration Rate
3.4.1 Top 3 Acute Migraine Medications Manufacturer Market Share
3.4.2 Top 6 Acute Migraine Medications Manufacturer Market Share
3.5 Global Acute Migraine Medications Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Acute Migraine Medications Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Acute Migraine Medications Market Size by Region
4.1.1 Global Acute Migraine Medications Sales in Volume by Region (2016-2026)
4.1.2 Global Acute Migraine Medications Revenue by Region (2016-2026)
4.2 North America Acute Migraine Medications Revenue (2016-2026)
4.3 Europe Acute Migraine Medications Revenue (2016-2026)
4.4 Asia-Pacific Acute Migraine Medications Revenue (2016-2026)
4.5 South America Acute Migraine Medications Revenue (2016-2026)
4.6 Middle East and Africa Acute Migraine Medications Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Acute Migraine Medications Sales in Volume by Type (2016-2026)
5.2 Global Acute Migraine Medications Revenue by Type (2016-2026)
5.3 Global Acute Migraine Medications Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Acute Migraine Medications Sales in Volume by Application (2016-2026)
6.2 Global Acute Migraine Medications Revenue by Application (2016-2026)
6.3 Global Acute Migraine Medications Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Acute Migraine Medications Sales by Type (2016-2026)
7.2 North America Acute Migraine Medications Sales by Application (2016-2026)
7.3 North America Acute Migraine Medications Market Size by Country
7.3.1 North America Acute Migraine Medications Sales in Volume by Country (2016-2026)
7.3.2 North America Acute Migraine Medications Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Acute Migraine Medications Sales by Type (2016-2026)
8.2 Europe Acute Migraine Medications Sales by Application (2016-2026)
8.3 Europe Acute Migraine Medications Market Size by Country
8.3.1 Europe Acute Migraine Medications Sales in Volume by Country (2016-2026)
8.3.2 Europe Acute Migraine Medications Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Acute Migraine Medications Sales by Type (2016-2026)
9.2 Asia-Pacific Acute Migraine Medications Sales by Application (2016-2026)
9.3 Asia-Pacific Acute Migraine Medications Market Size by Region
9.3.1 Asia-Pacific Acute Migraine Medications Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Acute Migraine Medications Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Acute Migraine Medications Sales by Type (2016-2026)
10.2 South America Acute Migraine Medications Sales by Application (2016-2026)
10.3 South America Acute Migraine Medications Market Size by Country
10.3.1 South America Acute Migraine Medications Sales in Volume by Country (2016-2026)
10.3.2 South America Acute Migraine Medications Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Acute Migraine Medications Sales by Type (2016-2026)
11.2 Middle East & Africa Acute Migraine Medications Sales by Application (2016-2026)
11.3 Middle East & Africa Acute Migraine Medications Market Size by Country
11.3.1 Middle East & Africa Acute Migraine Medications Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Acute Migraine Medications Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Acute Migraine Medications Typical Distributors
12.3 Acute Migraine Medications Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Acute Migraine Medications Revenue by Type, (USD Million), 2021-2026
Table 2. Global Acute Migraine Medications Revenue by Application, (USD Million), 2021-2026
Table 3. GSK Basic Information, Manufacturing Base and Competitors
Table 4. GSK Major Business
Table 5. GSK Acute Migraine Medications Product and Services
Table 6. GSK Acute Migraine Medications Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Teva Basic Information, Manufacturing Base and Competitors
Table 8. Teva Major Business
Table 9. Teva Acute Migraine Medications Product and Services
Table 10. Teva Acute Migraine Medications Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Pfizer Basic Information, Manufacturing Base and Competitors
Table 12. Pfizer Major Business
Table 13. Pfizer Acute Migraine Medications Product and Services
Table 14. Pfizer Acute Migraine Medications Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Novartis Basic Information, Manufacturing Base and Competitors
Table 16. Novartis Major Business
Table 17. Novartis Acute Migraine Medications Product and Services
Table 18. Novartis Acute Migraine Medications Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Merck Basic Information, Manufacturing Base and Competitors
Table 20. Merck Major Business
Table 21. Merck Acute Migraine Medications Product and Services
Table 22. Merck Acute Migraine Medications Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Sun Pharma Basic Information, Manufacturing Base and Competitors
Table 24. Sun Pharma Major Business
Table 25. Sun Pharma Acute Migraine Medications Product and Services
Table 26. Sun Pharma Acute Migraine Medications Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Grunenthal Basic Information, Manufacturing Base and Competitors
Table 28. Grunenthal Major Business
Table 29. Grunenthal Acute Migraine Medications Product and Services
Table 30. Grunenthal Acute Migraine Medications Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Endo Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. Endo Pharmaceuticals Major Business
Table 33. Endo Pharmaceuticals Acute Migraine Medications Product and Services
Table 34. Endo Pharmaceuticals Acute Migraine Medications Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global Acute Migraine Medications Sales by Manufacturer (2019-2021e) & (K Units)
Table 36. Global Acute Migraine Medications Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in Acute Migraine Medications, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global Acute Migraine Medications Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and Acute Migraine Medications Production Site of Key Manufacturer
Table 40. Acute Migraine Medications New Entrant and Capacity Expansion Plans
Table 41. Acute Migraine Medications Mergers & Acquisitions in the Past Five Years
Table 42. Global Acute Migraine Medications Sales by Region (2016-2021e) & (K Units)
Table 43. Global Acute Migraine Medications Sales by Region (2021-2026) & (K Units)
Table 44. Global Acute Migraine Medications Revenue by Region (2016-2021e) & (USD Million)
Table 45. Global Acute Migraine Medications Revenue by Region (2021-2026) & (USD Million)
Table 46. Global Acute Migraine Medications Sales by Type (2016-2021e) & (K Units)
Table 47. Global Acute Migraine Medications Sales by Type (2021-2026) & (K Units)
Table 48. Global Acute Migraine Medications Revenue by Type (2016-2021e) & (USD Million)
Table 49. Global Acute Migraine Medications Revenue by Type (2021-2026) & (USD Million)
Table 50. Global Acute Migraine Medications Price by Type (2016-2021e) & (US$/Unit)
Table 51. Global Acute Migraine Medications Price by Type (2021-2026) & (US$/Unit)
Table 52. Global Acute Migraine Medications Sales by Application (2016-2021e) & (K Units)
Table 53. Global Acute Migraine Medications Sales by Application (2021-2026) & (K Units)
Table 54. Global Acute Migraine Medications Revenue by Application (2016-2021e) & (USD Million)
Table 55. Global Acute Migraine Medications Revenue by Application (2021-2026) & (USD Million)
Table 56. Global Acute Migraine Medications Price by Application (2016-2021e) & (US$/Unit)
Table 57. Global Acute Migraine Medications Price by Application (2021-2026) & (US$/Unit)
Table 58. North America Acute Migraine Medications Sales by Country (2016-2021e) & (K Units)
Table 59. North America Acute Migraine Medications Sales by Country (2021-2026) & (K Units)
Table 60. North America Acute Migraine Medications Revenue by Country (2016-2021e) & (USD Million)
Table 61. North America Acute Migraine Medications Revenue by Country (2021-2026) & (USD Million)
Table 62. North America Acute Migraine Medications Sales by Type (2016-2021e) & (K Units)
Table 63. North America Acute Migraine Medications Sales by Type (2021-2026) & (K Units)
Table 64. North America Acute Migraine Medications Sales by Application (2016-2021e) & (K Units)
Table 65. North America Acute Migraine Medications Sales by Application (2021-2026) & (K Units)
Table 66. Europe Acute Migraine Medications Sales by Country (2016-2021e) & (K Units)
Table 67. Europe Acute Migraine Medications Sales by Country (2021-2026) & (K Units)
Table 68. Europe Acute Migraine Medications Revenue by Country (2016-2021e) & (USD Million)
Table 69. Europe Acute Migraine Medications Revenue by Country (2021-2026) & (USD Million)
Table 70. Europe Acute Migraine Medications Sales by Type (2016-2021e) & (K Units)
Table 71. Europe Acute Migraine Medications Sales by Type (2021-2026) & (K Units)
Table 72. Europe Acute Migraine Medications Sales by Application (2016-2021e) & (K Units)
Table 73. Europe Acute Migraine Medications Sales by Application (2021-2026) & (K Units)
Table 74. Asia-Pacific Acute Migraine Medications Sales by Region (2016-2021e) & (K Units)
Table 75. Asia-Pacific Acute Migraine Medications Sales by Region (2021-2026) & (K Units)
Table 76. Asia-Pacific Acute Migraine Medications Revenue by Region (2016-2021e) & (USD Million)
Table 77. Asia-Pacific Acute Migraine Medications Revenue by Region (2021-2026) & (USD Million)
Table 78. Asia-Pacific Acute Migraine Medications Sales by Type (2016-2021e) & (K Units)
Table 79. Asia-Pacific Acute Migraine Medications Sales by Type (2021-2026) & (K Units)
Table 80. Asia-Pacific Acute Migraine Medications Sales by Application (2016-2021e) & (K Units)
Table 81. Asia-Pacific Acute Migraine Medications Sales by Application (2021-2026) & (K Units)
Table 82. South America Acute Migraine Medications Sales by Country (2016-2021e) & (K Units)
Table 83. South America Acute Migraine Medications Sales by Country (2021-2026) & (K Units)
Table 84. South America Acute Migraine Medications Revenue by Country (2016-2021e) & (USD Million)
Table 85. South America Acute Migraine Medications Revenue by Country (2021-2026) & (USD Million)
Table 86. South America Acute Migraine Medications Sales by Type (2016-2021e) & (K Units)
Table 87. South America Acute Migraine Medications Sales by Type (2021-2026) & (K Units)
Table 88. South America Acute Migraine Medications Sales by Application (2016-2021e) & (K Units)
Table 89. South America Acute Migraine Medications Sales by Application (2021-2026) & (K Units)
Table 90. Middle East & Africa Acute Migraine Medications Sales by Country (2016-2021e) & (K Units)
Table 91. Middle East & Africa Acute Migraine Medications Sales by Country (2021-2026) & (K Units)
Table 92. Middle East & Africa Acute Migraine Medications Revenue by Country (2016-2021e) & (USD Million)
Table 93. Middle East & Africa Acute Migraine Medications Revenue by Country (2021-2026) & (USD Million)
Table 94. Middle East & Africa Acute Migraine Medications Sales by Type (2016-2021e) & (K Units)
Table 95. Middle East & Africa Acute Migraine Medications Sales by Type (2021-2026) & (K Units)
Table 96. Middle East & Africa Acute Migraine Medications Sales by Application (2016-2021e) & (K Units)
Table 97. Middle East & Africa Acute Migraine Medications Sales by Application (2021-2026) & (K Units)
Table 98. Direct Channel Pros & Cons
Table 99. Indirect Channel Pros & Cons
Table 100. Acute Migraine Medications Typical Distributors
Table 101. Acute Migraine Medications Typical Customers
List of Figures
Figure 1. Acute Migraine Medications Picture
Figure 2. Global Acute Migraine Medications Sales Market Share by Type in 2020
Figure 3. Triptans
Figure 4. NSAIDs
Figure 5. Others
Figure 6. Global Acute Migraine Medications Sales Market Share by Application in 2020
Figure 7. Drug Stores
Figure 8. Hospital Pharmacies
Figure 9. Global Acute Migraine Medications Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 10. Global Acute Migraine Medications Market Size and Forecast (2016-2026) & (USD Million)
Figure 11. Global Acute Migraine Medications Sales (2016-2026) & (K Units)
Figure 12. Global Acute Migraine Medications Price by Type (2016-2026) & (US$/Unit)
Figure 13. Global Acute Migraine Medications Production Capacity (2016-2026) & (K Units)
Figure 14. Global Acute Migraine Medications Production Capacity by Geographic Region: 2020 VS 2021
Figure 15. Acute Migraine Medications Market Drivers
Figure 16. Acute Migraine Medications Market Restraints
Figure 17. Acute Migraine Medications Market Trends
Figure 18. Global Acute Migraine Medications Sales Market Share by Manufacturer in 2020
Figure 19. Global Acute Migraine Medications Revenue Market Share by Manufacturer in 2020
Figure 20. Acute Migraine Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. Top 3 Acute Migraine Medications Manufacturer (Revenue) Market Share in 2020
Figure 22. Top 6 Acute Migraine Medications Manufacturer (Revenue) Market Share in 2020
Figure 23. Global Acute Migraine Medications Sales Market Share by Region (2016-2026)
Figure 24. Global Acute Migraine Medications Revenue Market Share by Region (2016-2026)
Figure 25. North America Acute Migraine Medications Revenue (2016-2026) & (USD Million)
Figure 26. Europe Acute Migraine Medications Revenue (2016-2026) & (USD Million)
Figure 27. Asia-Pacific Acute Migraine Medications Revenue (2016-2026) & (USD Million)
Figure 28. South America Acute Migraine Medications Revenue (2016-2026) & (USD Million)
Figure 29. Middle East & Africa Acute Migraine Medications Revenue (2016-2026) & (USD Million)
Figure 30. Global Acute Migraine Medications Sales Market Share by Type (2016-2026)
Figure 31. Global Acute Migraine Medications Revenue Market Share by Type (2016-2026)
Figure 32. Global Acute Migraine Medications Price by Type (2016-2026) & (US$/Unit)
Figure 33. Global Acute Migraine Medications Sales Market Share by Application (2016-2026)
Figure 34. Global Acute Migraine Medications Revenue Market Share by Application (2016-2026)
Figure 35. Global Acute Migraine Medications Price by Application (2016-2026) & (US$/Unit)
Figure 36. North America Acute Migraine Medications Sales Market Share by Type (2016-2026)
Figure 37. North America Acute Migraine Medications Sales Market Share by Application (2016-2026)
Figure 38. North America Acute Migraine Medications Sales Market Share by Country (2016-2026)
Figure 39. North America Acute Migraine Medications Revenue Market Share by Country (2016-2026)
Figure 40. United States Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Acute Migraine Medications Sales Market Share by Type (2016-2026)
Figure 44. Europe Acute Migraine Medications Sales Market Share by Application (2016-2026)
Figure 45. Europe Acute Migraine Medications Sales Market Share by Country (2016-2026)
Figure 46. Europe Acute Migraine Medications Revenue Market Share by Country (2016-2026)
Figure 47. Germany Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. France Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. United Kingdom Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Russia Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Italy Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Acute Migraine Medications Sales Market Share by Region (2016-2026)
Figure 53. Asia-Pacific Acute Migraine Medications Sales Market Share by Application (2016-2026)
Figure 54. Asia-Pacific Acute Migraine Medications Sales Market Share by Region (2016-2026)
Figure 55. Asia-Pacific Acute Migraine Medications Revenue Market Share by Region (2016-2026)
Figure 56. China Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Japan Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Korea Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. India Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Southeast Asia Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Australia Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South America Acute Migraine Medications Sales Market Share by Type (2016-2026)
Figure 63. South America Acute Migraine Medications Sales Market Share by Application (2016-2026)
Figure 64. South America Acute Migraine Medications Sales Market Share by Country (2016-2026)
Figure 65. South America Acute Migraine Medications Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East & Africa Acute Migraine Medications Sales Market Share by Type (2016-2026)
Figure 69. Middle East & Africa Acute Migraine Medications Sales Market Share by Application (2016-2026)
Figure 70. Middle East & Africa Acute Migraine Medications Sales Market Share by Country (2016-2026)
Figure 71. Middle East & Africa Acute Migraine Medications Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Egypt Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. South Africa Acute Migraine Medications Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界の抗片頭痛薬市場 2021：企業別、地域別、種類・用途別 The Anti-Migraine Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations…- 世界の急性気管支炎治療市場 2021：企業別、地域別、種類・用途別 The Acute Bronchitis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…
- 急性間欠性ポルフィリン症トリートメントの世界市場2018-2025 Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyr…
- 急性間欠性ポルフィリン症治療の世界市場2018-2025 Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyr…
- 急性間欠性ポルフィリン症薬の世界市場2018-2025 Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyr…